Life Sciences Archive » April, 2022

Life Sciences - April, 2022

313 articles

• 1 Split, 3 Vehicles: High Court's Paths To Bridging FCA Divide
• Theranos Investor Says Balwani Told Him Science Was Solid
• Fed. Circ. Says Skepticism Can't Save Robotic Surgery Patent
• 4th Circ. Sides With W.Va. Limit On Attys' Medication Case Ads
• Purdue Tells 2nd Circ. 30 Years Of Precedent Back Ch. 11 Plan
• Pharma Co. Sued For $12M For Underpaying Board Chair
• Ski Mogul Gets 5 Years In 'Massive' Vermont EB-5 Fraud Case
• Ranbaxy Buyers' $485M Deal In Generics MDL Gets Initial Nod
• Courts Are Unsettled On Obviousness-Type Double Patenting
• Sanitizer Co. Ch. 11 Loan Called Attempt To Dodge Liability
• Foley & Mansfield Adds Litigation Partner In New Orleans
• Goodwin Procter Adds Davis Polk Capital Markets Pro
• Law Firms Topple J&J Subpoenas For Talc Media Info
• MORE Act's Possible Impact On State-Licensed Cannabis Cos.
• Vaccine Maker's Upsized Offering Leads Pair Of Biotech IPOs
• Health Hires: Akin Gump, Katten
• Real Estate Rumors: Easton Group, WS Development, RFR
• Associates, Look Beyond Money In Assessing Lateral Offers
• UK Litigation Roundup: Here's What You Missed In London
• Medline Must Face Rival's Trimmed Misinformation Suit
• Feds Beat NJ Doctor's FOIA Suit Over DNA Docs
• Judge Slashes Suit Claiming MabVax Execs Duped Investors
• Turkey Takes WTO Loss On Drug Rules To Arbitration
• Prenatal Test Maker Faces Investor Suit Over False Positives
• Air Force Officer Can Seek Class Status In Vax Mandate Suit
• Restoring America Invents Act Should Not Do The Opposite
• ER Chief Says Opioid Crisis Feels 'Hopeless' At SF Bellwether
• Feds Push Back On Bid For $1.9M Fees In GMO Salmon Suit
• Bausch & Lomb Spinoff IPO Could Raise $788M
• FDA Proposes Menthol Ban In Cigarettes
• 2nd Circ. Doubts Ex-Shkreli Atty Can Keep BigLaw Nest Egg
• Preventing Impermissible Client Solicitation After ABA Opinion
• 4 Issues To Watch As Adult-Use Cannabis Sales Begin In NJ
• Hedge Fund Priest Seeks New Trial After 'Trivial' SEC Win
• Amgen Plans To Challenge Latest $7.1B Tax Bill From IRS
• COVID-19 Cases Won't Stop SF's Opioid Bellwether Trial
• Walgreens Opioid Inaction Preceded Fla. Shutdown, Jury Told
• Balwani Recruited His Dermatologist As Lab Chief, Jury Told
• 'Overheated Hyperbole'? Opioid Atty Gets Fiery In SF Trial
• 1st Circ. OKs Hospital's Denial Of Vax Mandate Exemptions
• Ark. Consulting Firm Wants Out Of Medical Pot Biz Suit
• Alcon Sues Over Alleged Eye Drop Patent Infringement
• Coloplast Hit With $2.5M Verdict In Pelvic Mesh Trial
• What FDA Expects From Medical Device Cybersecurity Efforts
• Purdue Ch. 11 Injunction Extended Pending 2nd Circ. Decision
• Real Estate Rumors: RRD International, Calta, Starbucks
• Teligent Gets Ch. 11 Disclosure, Voting Plans OK'd In Del.
• Express Scripts Wants Departing Attys To Aid Acthar Dispute
• CMA Gets Post-Brexit Cancer Drug Pricing Pact From Aspen
• Lessons On Avoiding E-Discovery Violations And Sanctions
• Buchanan Ingersoll Wants $1.9M From Ex-Client's Settlement
• 'Small Fish' Drugmakers Blame Purdue In SF Opioid Trial
• J&J Says Counterfeit Ring Selling 'Dangerous' HIV Meds
• Orrin Hatch's IP Influence Goes Far Beyond Generic Drugs
• AstraZeneca Sues Mylan Over Fresh Asthma Drug Patent
• Balwani Jurors Can Hear If Investors Knew He Dated Holmes
• States In Shkreli FTC Trial Told To Redo $2.2M Atty Fee Ask
• Week In Bankruptcy: InfoWars' Shaky Start, Releases Still Roil
• 2nd Circ. Affirms Shire Sanctions In Pharma IP Fight
• Allergy Co. Claims Trimmed As Untimely In Conspiracy Suit
• Juul Faces More Suits Over Marketing Vapes As 'Safe'
• A Quiet Change At The USPTO Creates A 2-Tier Exam Process
• Takeaways On The New Antitrust Scrutiny In Health Care
• Hospital Beats Title VII Claim Over Gender-Affirming Care
• FDA Allows NJOY E-Cigs To Stay On Market
• Counsel Leadership Fight Looms In Pharma Co. Pay Suit
• Fla. Doc Can't Dodge Fraudulent Fentanyl Fight With Feds
• Collaborative Tech Will Dictate Future Law Firm Success
• Philips Subpoenaed By DOJ Over Sleep Apnea Device Recall
• SF Opens Key Opioid Bellwether Trial Vowing To Reveal 'Lies'
• Health Network's Virus Coverage Suit Sent To State Court
• US Trustee Calls Teligent Ch. 11 Plan Releases 'Baffling'
• Shkreli Poses 'Serious Risk' Without Pharma Ban, Judge Says
• HHS Urged To Lower Drug Costs By 'Breaking Patent Barriers'
• 2nd Circ. Says Charge, Not Conviction, Enough To Void Bail
• $200M Shipping Accident Award Hasn't Been Paid, Co. Says
• Cannabis REIT Is A 'Marijuana Bank' In Disguise, Suit Says
• Chamber Backs Vitamin C Importers' Renewed High Court Bid
• Justices Won't Review Fed. Circ. Ruling Axing Drug Dosing IP
• Novartis Wants Rival's Atty Booted From MS Drug Patent Suit
• Catching Up With Delaware's Chancery Court
• How To Effectively Prepare A Witness For Remote Testimony
• Latham-Led Vax Developer Launches Plans For $175M IPO
• Mallinckrodt Creditors Can't Get Ch. 11 Plan Halted
• Law360's 2022 Life Sciences Editorial Advisory Board
• Ranbaxy Buyers Seek OK On $485M Deal In Generics MDL
• Balwani Never Told Theranos Lab Director To Lie, Jury Hears
• COVID Illness Delays Bard, AngioDynamics Patent Trial In Del.
• Cannabis Bill Roundup: SC Lawmaker Pitches '420 Day'
• Clinics Accused Of HIV Drug Scam Protest Asset Freeze
• Ex-Ermi Compliance Chief Loses Whistleblower Suit, For Now
• Officer Says Air Force Can't Stay Vaccine Mandate Suit
• Windy City Shuffle: Crowell & Moring, Benesch, Ballard Spahr
• A Crucial Element In Patent Prosecution: Examiner Experience
• Health Hires: Ichnos Sciences, Turnstone Biologics
• Expert's Sexual Abuse Conviction Jolts Formula Tariff Case
• As Cyber Risks Surge, Remember Attorneys' Ethical Duties
• Fla. Commissioner Sues DOJ Over Pot Patients' Gun Rights
• 'Our Heads Were Spinning': Trial Atty Explains Rare Strategy
• Environmental Coverage Disputes Continue Evolution In 2022
• UK Litigation Roundup: Here's What You Missed In London
• Bellwether By The Bay: Key Details As SF Opioid Trial Looms
• Calif. Judge Sends Aetna's HIV Drug Suit To State Court
• IP Forecast: 6th Circ. To Eye Seed Biz's $7M Trade Secret Win
• Disqualified Endo Judge Defends Facebook Posts On Opioids
• Ionis Pharmaceuticals Sued In Del. For Director Pay Docs
• US Trade Rep Downplays Reports Of COVID IP Waiver Deal
• Telemed Doctor Charged In $10M Prescription Fraud Scheme
• FibroGen Board, Officers Sued In Del. Over Drug Missteps
• New USPTO Head Sets Sights On Diversity, Arthrex Guidelines
• Former Biz Adviser Gets 18 Months For EB-5 Fraud Scheme
• Judge Admits 'Inexcusable' Error In Atty's SEC Fraud Trial
• Rethinking E-Discovery Readiness Amid Rise Of Collab Tools
• Fla. Court Reverses $3.25M In Damages In Engles Case
• Endo Reaches $10M Deal With SF Ahead Of Opioid Trial
• Balwani Can't Portray Gov't Witness As 'Bad Lab Director'
• Blackstone Wraps Up $1.6B Life Sciences Fund
• Ovarian Cancer Patients Want Louder Voice In J&J Unit Ch. 11
• NYC Workers Hit City With Vax Requirement Suit
• Akanda Buys Canadian Cannabis Co. Subsidiary For $28M
• Calif. Medical Cannabis Co. Loses Pot Farm Search Fight
• Health Cos. Could See More Conference Enforcement Risk
• GAO Won't Revisit View On Late Electronic Bids In FDA Case
• Troutman Pepper Adds 2 Corporate Partners From Cooley
• Wilson Sonsini Adds Goodwin M&A Expert In LA Office
• Alkermes, Janssen Enter Arbitration Over NanoCrystal Tech
• Embracing ESG: Uber Counsel Talks Safety Standards
• Endo Wins Reversal Of Opioid Default And Judge Is DQ'd
• Prospectively Appointing Jackson To High Court Is Unlawful
• Theranos Never Fulfilled Finger Stick Test Promise, Jury Hears
• Arbor, Lupin End IP Suit Over Planned Blood Pressure Generic
• Alabama AG Ends Opioid Holdout With Deals Worth $276M
• Ex-Attys For Dermagraft Whistleblower Nab $6M Fee Award
• Fed. Circ. Mulls UMass Bid To Revive L'Oreal Skincare IP Suit
• DOJ Says Teva, Like Glenmark, Can't Get Grand Jury Docs
• SEC Gets Consent Win For CEO's COVID-19 Product Claims
• Eye Docs Say Recordkeeper Hid Ransomware Attack Outages
• Injectable Drug Dropped From $375M Merger To Assuage FTC
• Strategies To Help Close IP Law's Long-Standing Gender Gap
• Wachtell, Goodwin Rep In Regeneron's $250M Biopharma Buy
• Calif. County Beats Couple's Pot License Denial Challenge
• Norton Rose Adds Brussels Antitrust Pro From Covington
• Gibson Dunn Adds Biopharma IP Partner From Ropes & Gray
• Ex-Aegerion Rep Owes $1.6M To Fraud Victims, Feds Say
• Johns Hopkins Beats $1B Guatemalan Syphilis Study Suit
• New Court Takes The Wheel In NY's Vast Opioid Litigation
• Conn. Atty Can't Redo Trial Over Alleged Jury Talk, SEC Says
• Conformis Asks 1st Circ. To Save Knee Implant Coverage Row
• ACLU Says Nevada Pot Schedule I Status Unconstitutional
• Ark. Medical Pot Regulator Can't Exit Suit Over License Denial
• Big Cos. Shouldn't Cry 'Settlement Pressure' To Justify Appeal
• Consumers Win Cert. Of Dietary Supplement False Ad Class
• Justices Want SG's Take On Enablement In Antibody IP Fight
• The Rise Of Cannabis Mobile Commerce
• Catching Up With Delaware's Chancery Court
• Tela Bio Hires Life Sciences Atty As 1st GC
• Latham, Davis Polk Steer ArchiMed's $1.2B Natus Medical Deal
• Opioid Trial Gamble Pays Off For W.Va. In $99M Deal With J&J
• CR Bard Hit With $250K Verdict In 2nd Hernia Mesh Bellwether
• Jury Told Balwani Provided Theranos' Investor Financial Data
• Roche Ruling Highlights High Bar For Induced Infringement
• Cannabis Bill Roundup: NH Lawmakers Mull Home Grow
• Air Force Seeks To Halt Officer's Vax Mandate Suit
• Exec, Son Settle Insider Trading Suit Over COVID Test Deal
• DaVita, Ex-CEO Acquitted In Antitrust No-Poach Trial
• Access Bio, Others Hit Back At $1B 'Windfall' Virus Test Suit
• Albright Maintains Popularity In Early '22 As NPEs Slow Down
• Priest Facing Possible SEC Ban Wants Appeal Heard First
• Time To Fix Legal Industry's Environmental Pro Bono Problem
• Health Hires: CSafe Global, Alumis
• Newborn Opioid Victim Group Says Sackler Releases Justified
• Firm Loses Bid To DQ Atty In Flint Water Crisis Litigation
• Biotech Co. To Pay $4M To End Presentation Hype Suit
• Don't Miss It: Kirkland, Skadden Guide Week's Hot Deals
• Radiology Chain Exec Stiffed Workers In Stock Plan, Suit Says
• Patent Strategy Considerations After Caltech Estoppel Ruling
• 4 Ways Lawyers Keep Busy When Public Markets Are Shut
• Taxation With Representation: Cleary, Simpson Thacher
• Monsanto Judge Pondering $45M Roundup False Ad Deal
• IP Forecast: NetScout To Wrestle With Patent Biz In Texas
• NY Pot Regulators Approve First Adult-Use Grower Licenses
• Zetia Wholesalers Denied Class Cert. In Generics-Delay Suit
• Science Group Sues Homeopathic Co. Over 'Quackery' Drugs
• Changes To Watch In China's Human Genetic Resources Regs
• Biotech Co. Owes NY Tax On Royalties From Foreign Affiliates
• Keller & Heckman Adds Ex-GC From CBD And Tobacco Cos.
• SG Must Take A Stand On Medical Cannabis Reimbursement
• Remembering An Underappreciated Legal Skill — Listening
• Rutgers Students Can't Hide Names In COVID Vaccine Suit
• Ga. Anesthesia Biz Pays $7M To End Kickbacks Case
• Ex-DaVita CEO's 'Feelings' Drove No-Poach Crimes, DOJ Says
• Balwani Jury Can See Theranos' Failed Deals With Military
• Ex-Hospitals Owner Hits Medtronic With $1.3M Clawback Suit
• Report Says McKinsey Hid Conflicts In Advising FDA, Purdue
• DOJ Kickback Concerns Extend Beyond Federal Funds
• Medical Researcher Says DEA Stonewalled Pot Applications
• Attorneys Can Promote Trade, Security Amid Global Conflict
• Cooley Life Sciences IP Team Departs To Mintz Boston Office
• Uncertainty Clouds Attys' Strategies For Pursuing IP In Russia
• 'Vexatious' Ex-MLB Player Abused Court System, Alsup Says
• Cipla Calls Achaogen Claims Over Lost Ch. 11 Sales 'Weak'
• GenapSys Ex-CEO Sues Twice In Del. After Company Fallout
• Drug Cos. Must Face Bulk Of Weight Loss Drug Cancer Suit
• Cleary, Wilson Sonsini Lead GSK's $1.9B Sierra Oncology Buy
• Ex-DaVita CEO Denies Anti-Poach 'Intent' As Feds Rest
• Fresenius GC Says He Was Canned For Flagging Misconduct
• Wash. AG And Distributors Abruptly Shelve Opioid Trial Finale
• Mapping The Top Trials To Know In The Opioid Litigation Wave
• ​​​​​​​Duane Morris Says Shkreli Owes It $2M In Bid To Drop Client
• Profs Tell Justices Not To Let Courts Decide Int'l Relations
• Merck Escapes False Ad Suit Over Shingles Vaccine
• 11th Circ. Undermined Rare-Disease Drugs, High Court Told
• J&J Must Face Impending Fraud Suit During Talc Unit's Ch. 11
• FDA Bashes Bausch Over Lifetime Talk Show Segment
• COVID-19 Test Supplier Ordered To Return $2M To Retailer
• J&J Unit Trims Mesh False Ad Loss To $302M On Appeal
• Feds Say Holmes' Conviction In Theranos Trial Should Stand
• Fed. Circ. Partly Backs PTAB Bone Graft Patent Decisions
• Teligent OK'd For Fast-Tracked Del. Ch. 11 Disclosure Hearing
• Insurers Want Out Of $16M Medical Device Co. Deal With DOJ
• Walgreens Execs Saw Profit In Opioid Crisis, Fla. Jury Told
• Ex-UChicago Prof Admits Trading On Inside Drug Trial Info
• Fed. Circ. Revives Catheter IP In Fight Against Abbott Unit
• Arthrex Sues For Coverage Of Settled FCA Claims
• The Future Of Legal Ops: Reining In Outside Counsel Costs
• Despite 'Hurt Feelings,' Bid To Intervene In Opioid Deal Denied
• In Surprise Move, Panel Stops Adding Cases To Opioid MDL
• Exec Admits DaVita No-Poach Deal In 'Painful' Testimony
• PTAB To Review Cancer Antibody IP That Drew $41.8M Verdict
• Hemp-Seizing Calif. County Slams Co.'s Illegal Warrant Claim
• Split Fed. Circ. Wipes Roche's $137M IP Loss, Calls For Redo
• Big Pharma Can't Beat SF Opioid Claims Before Trial
• Fed. Circ. Nixes Order Upholding Biogen IP It Also Invalidated
• DC Circ. Denies Hospital's Appeal In Specialty Doctor Pay Row
• When Congress Seeks Cos.' Nonpublic Info From Regulators
• Health Care Is In DOJ's Criminal Antitrust Crosshairs
• Ex-Yankee Stadium Worker Sues Over NYC Vax Rule Carveout
• Biopharm Co. Tarveda To Liquidate In Del. Chancery Court
• 'One Of The Family': Why Trial Attys Love Their Local Counsel
• IPO Outlook Slightly Brightens After A Dismal Start To 2022
• Daiichi Hit With $41.8M Verdict In Cancer Drug IP Fight
• UK Litigation Roundup: Here's What You Missed In London
• Calif. Doc Asks High Court To Review COVID-19 Trial Pause
• Split 5th Circ. Revives Biden's Federal Worker Vax Mandate
• Gilead Says Aetna Must Litigate Its HIV Drug Suit In Fed Court
• IP Forecast: Norton Fights Patent Suit, Armed With New Attys
• Amarin Downplayed Threat Of Vascepa Fight, Investor Says
• Bio-Rad Rival Wants Its COVID Test Tech Cleared Of IP Claims
• PTAB Launches Rare Derivation Review Over Stabilization IP
• Ga. Judge Walks Back Refusal To Toss Wrongful Death Suit
• Bristol-Myers Blood Thinner Patent Invalidated In UK
• Wisconsin Tribe Sues McKinsey Over Role In Opioid Crisis
• In Early Mediation, Negotiate With Empathy, Not Threats
• Animal Hospital Co.'s Bid To End 401(k) Fee Suit Falters
• The USPTO May Be Miscalculating Patent Term Adjustments
• Vanda Wants FDA Info Behind Label Expansion Denial
• ITC Blocks In Vitro Drug Imports Infringing Merck Unit's TM
• Teva Appears Headed For $100M Price-Fixing Payout To AGs
• Fenwick Adds Latham Corporate Atty In Calif.
• Arnold & Porter, 'Dragged Through Mud,' Touts Opioid Probe
• Calif. Naturopathic Doctor Cops To Peddling Fake Vax Cards
• DaVita Rival Felt Threatened Around Poaching, Jury Hears
• Atty Says Failure To Poll Jury In SEC Suit Warrants New Trial
• Balwani Jury Can See Evidence Theranos Used Pharma Logos
• Ruling Favoring Insurers In Opioid Suits May Set Precedent
• China Tariff Clash Leaves Sliver Of Hope For Importers
• US Trustee Urges 2nd Circ. To Reject Sackler Opioid Releases
• Hyman Phelps & McNamara Co-Founder Dies At 83
• Addressing Problematic Drinking In The Legal Profession
• Law Groups Back Suit Over Use Of Henrietta Lacks' Cells
• Rulings, FDA Guidance May Help Food Cos. In Protein Suits
• Cleanup Co. Pays $1.4M To End Wages Claim With NY DOL
• Titan Of The Plaintiffs Bar: Joseph Saveri's Steven Williams
• 'Tomorrow Is A New Day,' Theranos Judge Tells Balwani Atty
• 'Intense Pressure' To Ink Opioid Deal? Too Bad, 6th Circ. Says
• Jackson Addresses Host Of IP Issues In Guarded Comments
• Express Scripts, Mylan Get EpiPen Price Gouging Suit Cut
• Valsartan MDL Judge OKs Out-Of-State Litigants, More Claims
• 7th Circ. Won't Revive False Claims Act Suit Against Safeway
• US Cos. Rebound From Dip In European Patent Applications
• Transforming Law Firms' Diversity Intent Into Real Progress
• Where DOJ Is Heading On Consumer Protection Enforcement
• Pennsylvania CBD Sellers Say Franchiser Cheated Them
• Split 8th Circ. Upholds Dismissal Of Biotech Contract Suit
• Norton Rose Picks Up 11 Blackwell Burke Attys In Minneapolis
• W.Va. AG Blames 3 Opioid Makers As Trial Opens
• Regeneron 'Kickbacks' Boosted Eylea Profits, Insurer Says
• Opioid MDL Judge Cites Miss Piggy To Explain Time Limits
• Teva, Like Glenmark, Rips Expanded Price-Fixing Charges
• Medical Pot Biz Says Ark. Licenses Steered To Big Cos.
• House Approves Bipartisan Medical Marijuana Research Bill
• More Than 20 Law Firms Led Q1's Top 10 Global M&A Deals
• Parts Of Oklahoma PBM Law Invalidated By Judge
• Lab Execs, Texas Hospital Staff Hit With DOJ Kickback Suit
• Gunderson Dettmer Adds Boston Atty As Employment Partner
• Ga. Court Sends Medical Device Patent Dispute To Md.
• Catching Up With Delaware's Chancery Court
• Justices Urged To Scrutinize 'Bad Faith' FCA Defenses
• Sanofi GC Will Sit On 'First-In-Pharma' Diversity Board
• Jury Finds Connecticut Attorney Ran Stock Sale Scheme
• Justices Must Apply Law Evenly In Shadow Docket Rulings
• 'Don't Threaten Me,' Judge Warns Balwani Atty At Fraud Trial
• ​​​​​​​PureWick Wins $28M Jury Verdict In Catheter Patent Suit
• 9th Circ. Asks Calif. High Court To Decide Shock Therapy Suit
• UK Social Care Biz Receives Possible £821M Takeover Bid
• 11th Circ. Won't Revive False Claims Suit Against HIG Capital
• Vitamin Shoppe Beats Suit Over Muscle Supplements
• Inovio Stockholder Sues In Del. Over COVID Vaccine Claims
• New Horse-Doping Regulator Defeats Constitutional Challenge
• Bayer And J&J Beat FCA Suit Over Antibiotics Claims
• Health Hires: Locke Lord, Essential Pharma
• Tips For Negotiating Litigation Funding Agreements
• Jones Day Snags 3rd Former King & Spalding Atty In Atlanta